Pharmaceutical Price Regulation Scheme

(asked on 28th January 2015) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health, what the value of rebate payments from the Pharmaceutical Price Regulation Scheme was to (a) Scotland, (b) Wales and (c) Northern Ireland in each quarter that scheme has operated.


Answered by
George Freeman Portrait
George Freeman
This question was answered on 2nd February 2015

The Government recognises that the Pharmaceutical Price Regulation Scheme (PPRS) payments that companies make under the 2014 scheme in respect of the United Kingdom need to be allocated to each of the devolved administrations in a fair way.

The aggregate payment received from pharmaceutical companies by the Department in Quarter 1 of the 2014 PPRS was £73,779,969 which was apportioned to the devolved health administrations on the basis of primary care data for licensed branded medicines relating to 2012-13, in each country. Accordingly, Scotland received £7,194,507.98, Wales received £4,011,404.61 and Northern Ireland received £2,989,371.81.

The method for apportioning payments for the remaining quarters of the PPRS will continue to be based on primary care data for spend on licensed branded medicines, as the most consistent data set available across the UK, but will be apportioned using prescribing data for the same period as the income relates. Further payments for the later quarters of the 2014 PPRS will be made once the Department is in receipt of the relevant data from the devolved administrations.

Reticulating Splines